NEW ORLEANS, June 2 /PRNewswire/ -- Dr. Charles Kerber, University of California San Diego, reported today at the American Society of Neuroradiology Conference in New Orleans the early results on the use of a new technology, Neucrylate(TM), to treat cerebral aneurysms. Neucrylate is a liquid embolic that has been developed by Valor Medical, a San Diego, CA, medical device company. "The patients have had very positive results and to date the accumulated patient implant times have reached 1400 days," Dr. Kerber stated.
The implant procedure begins by placing a microcatheter into an artery in the groin and then is passed up into the brain. This catheter is positioned in the aneurysm and Neucrylate is injected into the aneurysm. When Neucrylate comes in contact with the blood in the aneurysm it changes from a liquid to a sponge-like material. Once the catheter is in place the treatment time is approximately 1 -2 minutes.
Dr. Sean Pakbaz, University of California San Diego, has performed all the implants to date. "The more I use Neucrylate the more I'm impressed with how it works. Reducing the time it takes to treat an aneurysm is always a major goal when working in the brain. Implanting Neucrylate takes a lot less time than implanting coils. Neucrylate also fills the aneurysm compared to coils which only fill 30-40% of the aneurysm," Dr. Pakbaz stated.
Clark Adams, CEO, said, "Valor Medical is very excited with the early results from our clinical trials. Valor will be expanding the trial sites in Europe within a few months and we expect to begin trials in the U.S. later this year. The company anticipates launching Neucrylate in Europe by early 2010".
|SOURCE Valor Medical|
Copyright©2008 PR Newswire.
All rights reserved